New drug keeps blood pressure improved for two years after treatment stops in some patients, study finds
A new study reports that blood pressure stayed improved for up to two years after some patients stopped taking baxdrostat, raising hopes for a longer-lasting treatment, though researchers say the findings are preliminary.
Translated from Arabic. Read the original بالعربية
LONDON — A recent medical study has reported encouraging results for a treatment that targets a hormonal cause of high blood pressure, after some patients continued to improve for up to two years after they stopped taking the drug.
However, the researchers stress that the findings are preliminary. They do not mean a definitive cure has been found for everyone with high blood pressure, or that medication can be stopped without medical supervision.
The results were published in the New England Journal of Medicine on Nov. 7 and were led by researchers from Queen Mary University of London.
What problem does the treatment target?
The research focuses on a condition called primary aldosteronism, a known hormonal cause of high blood pressure.
Medical estimates link it to about five to 10 per cent of high blood pressure cases, with the proportion varying depending on which patients are screened.
The body produces the hormone aldosterone in the two adrenal glands above the kidneys to help regulate water and salt.
When its production rises abnormally, the body retains sodium and fluids, which raises blood pressure and can be accompanied by low potassium.
This cause may go undiscovered for years because patients receive blood pressure medication without specialized hormone testing.
Identifying the hormonal cause matters because the treatment options differ from those for common high blood pressure, and appropriate testing may help guide care more precisely.
How does the new drug work?
The scientists used the drug baxdrostat, which inhibits the enzyme responsible for making aldosterone in the adrenal gland.
This approach differs from drugs such as spironolactone and eplerenone, which block the hormone's effect after it has been produced, and from surgery, which is used for some suitable cases.
Participants followed a protocol called Extended Aldosterone Synthase Inhibition, abbreviated as EASI, for a period ranging from six months to a year.
The researchers aimed to test whether continued intervention could produce a longer-lasting change that extends beyond the period of taking the pills.
What did the patient results show?
The follow-up covered 14 patients treated at eight medical centres in the United States, a small number that is not enough to draw general conclusions.
After treatment was stopped, participants continued to show signs of improvement over follow-up periods of up to two years.
The researchers recorded a drop of about 99 per cent in the aldosterone-to-renin ratio compared with pre-treatment values.
Blood pressure also fell by an average of roughly 25 mmHg, and about a quarter of participants reached normal levels without other blood pressure medication.
However, these results do not prove the disease disappears permanently, and they do not mean all participants gave up their usual treatment.
Why are scientists discussing a possible cure?
The researchers hypothesize that suppressing hormone production for a long period may affect the cells responsible for the excess secretion, rather than only temporarily switching off their activity.
The idea is based in part on earlier laboratory experiments, but the same cellular change has not yet been shown in humans.
The researchers said a new trial called ELIXIR will use specialized imaging techniques to study the adrenal glands and test this possibility.
The current study was also not a large randomized trial comparing the treatment with a group taking a placebo.
Has the treatment received official approval?
In May 2026, the U.S. Food and Drug Administration approved baxdrostat, sold under the name Baxfendi, for adults whose blood pressure is not controlled despite the use of other medications.
The approval was based on larger trials that showed the drug was effective in lowering blood pressure while in use alongside usual treatment.
However, the approval does not include a claim that it permanently cures the disease after a limited course of treatment, a hypothesis that is still under investigation.
Important warning for patients
The drug can cause high potassium, low sodium or low blood pressure, so treatment requires monitoring of salt levels and kidney function.
No patient should stop their current medications or try the drug on their own based on these results.
Consulting a doctor is also necessary to determine whether aldosterone and renin testing is needed, especially when blood pressure is hard to control with prescribed treatments.
The study's main message is that a more targeted treatment could be developed for some causes of high blood pressure, not that long-term treatment is ending for all patients.
More from Hala Canada
- Six Toronto suspects on Canada's most wanted list, with rewards of up to $150,000 for two
- Pedestrian dies after being struck by vehicle in Mississauga; Peel police investigating
- Quebec to charge new fees on electric and plug-in hybrid vehicles from January 2027
- Man wanted in Ontario murder case arrested hours after being named to list of Canada's 25 most wanted
- KPMG Canada reports cyber incident involving unauthorized access to clients' tax documents
- Carney avoids position on Quebecor's $31-billion bid for Telus, stresses competition